Yan Leyfman, Co-Founder and Executive Director of MedNews Week, shared on LinkedIn:
“What if the next breakthrough in colorectal cancer screening isn’t simply detecting cancer earlier, but preventing more cancers from developing in the first place?
Grateful to share that our review has been recognized as an Editor’s Choice.
While current stool-based screening technologies have transformed noninvasive colorectal cancer detection, identifying advanced precancerous lesions remains a major unmet need.
Together with Dr. Arturo Loaiza-Bonilla and our collaborators, we explore how integrating host DNA methylation, gut microbiome signatures, and explainable AI could help address this gap.
Our scenario modeling suggests that improving advanced precancerous lesion sensitivity from approximately 43% to 55–65%, while maintaining ~94% specificity, could potentially identify 13–23 additional advanced precancerous lesions per 1,000 individuals screened.
Beyond the technology, we outline a translational roadmap emphasizing rigorous validation, reproducibility, and real-world clinical implementation.
The future of cancer screening should not simply be about finding cancer earlier. It should be about preventing more cancers before they begin.
Grateful to Dr. Arturo LoAIza-Bonilla for his continued mentorship and to our collaborators across St. Luke’s University Health Network and Massive Bio for their contributions.
Excited to see how multi-omics and AI can help move precision prevention closer to clinical reality.”
Title: Defining a Multi-Omic, AI-Enabled Stool Screening Paradigm for Colorectal Cancer: A Consensus Framework for Clinical Translation
Authors: Arturo Loaiza-Bonilla, Yan Leyfman, Viviana Cortiana, Rhys Crawford, Shivani Modi
- Agenus Reports 51% 18-Month Survival With BOT+BAL in MSS Colorectal Cancer
- ctDNA Blood Tests in Colorectal Cancer Screening: High Specificity, Limited Detection of Precancerous Lesions
